Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $49K fell 99.7% year over year, behind the -99.1% change in trailing-twelve-month cost of revenue.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -99.7% toward the trailing-twelve-month pace of -99.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$49K— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$149K-99.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.7%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -99.1% is the 7th highest of 8, against a peer median of -75.2%.
CRBP Competitors
Cost of Revenue for CRBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$29.7M USD-64.0%—161.2%
CRDFCardiff Oncology, Inc.LTM Mar 2026$11.58M USD+18.8%—2205.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
PEPGPepGen Inc.LTM Mar 2026$1.72M USD+351.6%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$161K USD——5.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$149K USD-99.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$95K USD——5.3%
FBRXForte Biosciences, Inc.LTM Mar 2026$6K USD-86.0%——
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding CRBP) —-75.2%-30.4%5.3%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue881.71K0000
Cost of Revenue1.64M1.49M0600K0
Gross Profit(757.53K)(1.49M)0(600K)0
Gross Margin-85.9%————
Research & Development36.45M16.14M31.17M32.22M70.1M
Selling, General & Admin20.43M18.7M13.91M16.5M15.22M
Operating Expenses55.23M33.35M45.08M48.12M85.31M
Depreciation & Amortization1.64M1.49M641K600K233K
EBITDA(42.17M)(38.73M)(40.11M)(37.74M)(78.3M)
EBITDA Margin-4782.9%————
Operating Income(55.99M)(34.84M)(45.08M)(48.72M)(85.31M)
Operating Margin-6350.1%————
Interest Income0006.31M5.53M
Interest Expense1.83M2.13M2.92M1.87M0
Other Income / Expenses10.35M(7.51M)474K8.51M6.77M
Income Before Tax(45.64M)(42.35M)(44.6M)(40.21M)(78.54M)
Pre-Tax Margin-5176.4%————
Income Tax Expense00000
Net Income(45.55M)(55.83M)(44.6M)(40.21M)(78.54M)
Net Margin-5166.4%————
EPS (Basic)(11.13)(10.15)(10.31)(3.68)(5.90)
EPS (Diluted)(11.13)(10.15)(10.31)(3.68)(5.90)
Weighted Avg Shares4.1M4.17M4.33M10.92M13.32M
Weighted Avg Shares (Diluted)4.1M4.17M4.33M10.92M13.32M

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.